Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFIXFc in previously untreated patients with severe hemophilia B
2013-003629-27Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eftrenonacog alfa in hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Occurrence of inhibitor development. Started Mar 2014; status: completed.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2013-003629-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003629-27.